NCT05765279View on ClinicalTrials.gov

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

NACompletedINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

December 6, 2022

Study Completion Date

December 6, 2022

Conditions
SARS-CoV-2 Infection
Interventions
DRUG

HH-120 nasal spray 1

HH-120 nasal spray 5 times daily for 3 consecutive days

DRUG

HH-120 nasal spray 2

HH-120 nasal spray 8 times daily for 3 consecutive days

DRUG

Placebo Comparator 1

Placebo nasal spray 5 times daily for 3 consecutive days

DRUG

Placebo Comparator 2

Placebo nasal spray 8 times daily for 3 consecutive days

Trial Locations (1)

100015

Beijing Ditan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Ditan Hospital

OTHER